Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5786321 | 0.90 | HRH3 (0.58) | HRH3 | |
| SCHEMBL5791485 | 0.90 | HRH3 (0.56) | HRH3ALDH1A1SMN1; SMN2 | |
| SCHEMBL5784910 | 0.87 | HRH3 (0.55) | HRH3ALDH1A1 | |
| SCHEMBL5785958 | 0.86 | HRH3 (0.56) | HRH3ALDH1A1 | |
| SCHEMBL5787870 | 0.84 | HRH3 (0.52) | HRH3SMN1; SMN2LTA4H | |
| SCHEMBL5785908 | 0.84 | HRH3 (0.62) | HRH3LTA4H | |
| SCHEMBL5790050 | 0.84 | HRH3 (0.62) | HRH3LTA4H | |
| SCHEMBL5789389 | 0.84 | HRH3 (0.54) | HRH3 | |
| SCHEMBL5785524 | 0.83 | HRH3 (0.56) | HRH3SMN1; SMN2 | |
| SCHEMBL5788733 | 0.83 | HRH3 (0.58) | HRH3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1720847-A1 | HISTAMINE-3 RECEPTOR MODULATORS | Pfizer Products Incorporated (US) | 2006-11-15 | — | — | EP | claimed |
| US-7115600-B2 | Histamine-3 receptor modulators | PFIZER INC. (US) | 2006-10-03 | — | — | US | claimed |
| WO-2005080361-A1 | HISTAMINE-3 RECEPTOR MODULATORS | PFIZER PRODUCTS INC. (US) | 2005-09-01 | — | — | WO | claimed |
| US-20050171181-A1 | 3-Benzyloxymethyl-1-(4-pyrrolidin-1-ylmethyl-phenyl)-cyclobutanol for example; treating allergies and mood disorders; use in combination with a histamine H1 antagonist or a neurotransmitter re-uptake blocker | PFIZER INC | 2005-08-04 | — | — | US | claimed |
| EP-1720847-A1 | HISTAMINE-3 RECEPTOR MODULATORS | Pfizer Products Incorporated (US) | 2006-11-15 | — | — | EP | disclosed |
| US-7115600-B2 | Histamine-3 receptor modulators | PFIZER INC. (US) | 2006-10-03 | — | — | US | disclosed |
| WO-2005080361-A1 | HISTAMINE-3 RECEPTOR MODULATORS | PFIZER PRODUCTS INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| US-20050171181-A1 | 3-Benzyloxymethyl-1-(4-pyrrolidin-1-ylmethyl-phenyl)-cyclobutanol for example; treating allergies and mood disorders; use in combination with a histamine H1 antagonist or a neurotransmitter re-uptake blocker | PFIZER INC | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171181-A1 | 3-Benzyloxymethyl-1-(4-pyrrolidin-1-ylmethyl-phenyl)-cyclobutanol for example; treating allergies and mood disorders; use in combination with a histamine H1 antagonist or a neurotransmitter re-uptake blocker | HRH3, HRH4, HRH1 | HRH3 1/4885ALDH1A1 927/4885SMN1; SMN2 1568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.